%0 Journal Article
%A Jaramillo, Sonia
%A Krisam, Johannes
%A Le Cornet, Lucian
%A Kratzmann, Markus
%A Baumann, Lukas
%A Eissymont, Olga
%A Crysandt, Martina
%A Görner, Martin
%A Kayser, Sabine
%A Krause, Stefan
%A Schliemann, Christoph
%A Gaska, Tobias
%A Kaufmann, Martin
%A Chemnitz, Jens
%A Schaich, Markus
%A Hoellein, Alexander
%A Platzbecker, Uwe
%A Kieser, Meinhard
%A Müller-Tidow, Carsten
%A Schlenk, Richard
%T Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
%J Haematologica
%V 109
%N 6
%@ 0390-6078
%C Pavia
%I Ferrata Storti Foundation
%M DKFZ-2024-01199
%P 1973-1976
%D 2024
%Z #LA:W010#
%K Humans
%K Gemtuzumab: therapeutic use
%K Gemtuzumab: administration & dosage
%K Leukemia, Myeloid, Acute: drug therapy
%K Leukemia, Myeloid, Acute: diagnosis
%K Antineoplastic Combined Chemotherapy Protocols: therapeutic use
%K Antineoplastic Combined Chemotherapy Protocols: adverse effects
%K Aminoglycosides: therapeutic use
%K Aminoglycosides: administration & dosage
%K Double-Blind Method
%K Male
%K Female
%K Middle Aged
%K Remission Induction
%K Aged
%K Induction Chemotherapy
%K Adult
%K Treatment Outcome
%K Benzimidazoles
%K Phenylurea Compounds
%K Gemtuzumab (NLM Chemicals)
%K Aminoglycosides (NLM Chemicals)
%K glasdegib (NLM Chemicals)
%K Benzimidazoles (NLM Chemicals)
%K Phenylurea Compounds (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38385304
%2 pmc:PMC11141665
%R 10.3324/haematol.2023.284346
%U https://inrepo02.dkfz.de/record/290602